Subscribe To

Price Alert Latest News Economic Calendar News

DMAC / DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group Elemer Piros - ROTH Capital Partners Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2022 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section. Read More

Demo Live Account See Partner Details

Content Topics

Diamedica

Therapeutics

Inc

DMAC

Rick

Pauls

2022

Results

dmac

Earnings

Transcript

Stock

Posted: Aug 11 2022, 12:01

Author Name: Seeking Alpha

DMAC News

By Seeking Alpha
May 16, 2023

DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Ch

By Business Wire
May 8, 2023

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing r

By Seeking Alpha
March 29, 2023

DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Rick Pauls - President and

By Business Wire
March 20, 2023

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing r

By Business Wire
March 13, 2023

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treat

By Seeking Alpha
August 11, 2022

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Rick Pauls - President and

By Business Wire
August 4, 2022

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treat

By Benzinga
July 7, 2022

FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why

The FDA placed a clinical hold on DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Phase 2/3 ReMEDy2 trial evaluating DM199 to treat acute ischemic st

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Subscribe To

Live Trading Account

Open live account in few minutes with just 10$

DMAC / DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript

Diamedica

Therapeutics

Inc

DMAC

Rick

Pauls

2022

Results

dmac

Earnings

Transcript

Stock

DMAC News

DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why